Ovarian Cancer | Specialty

The ovarian cancer condition center is a comprehensive resource for clinical news and expert insights on ovarian cancer. Read more at OncLive.

TUB-040 Represents Novel ADC Approach in Platinum-Resistant Ovarian Cancer

December 3rd 2025

Antonio González-Martín, MD, PhD, discusses data for TUB-040 in platinum-resistant ovarian cancer and how it stacks up against other ADCs.

Maintenance Fuzuloparib Displays PFS Benefit in Newly Diagnosed, Advanced Ovarian Cancer

December 3rd 2025

Fuzuloparib extended PFS vs placebo regardless of the addition of apatinib in newly diagnosed advanced ovarian cancer.

Revisit Every OncLive On Air Episode From November 2025

December 2nd 2025

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Experts Unpack the Most Notable NCCN Guideline Changes Heading Into 2026

December 1st 2025

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Dr Gonzalez-Martin on the NAPISTAR1-01 Trial of TUB-040 in Ovarian Cancer

November 28th 2025

Antonio Gonzalez-Martin, MD, discusses the design of the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

Five Under 5: Top Oncology Videos for the Week of 11/16

November 23rd 2025

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

The Essential But Often Complex Role of Numbers and Measurements in Oncology

November 20th 2025

Maurie Markman, MD, discusses the evolving role of measurements in cancer care.

Dr Gonzalez-Martin on the Rationale for Targeting NaPi2b in Ovarian Cancer

November 19th 2025

Antonio Gonzalez-Martin, MD, discusses the rationale for targeting NaPi2b in ovarian cancer.

Efforts to Leverage NaPi2b Are Renewed With Novel ADC in Ovarian Cancer

November 13th 2025

Initial activity and safety with the investigational ADC TUB-040 in ovarian cancer have renewed interest in NaPi2b as a target for ADC development.

Five Under 5: Top Oncology Videos for the Week of 11/2

November 9th 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer and ovarian cancer.

Dr Colombo on the Rationale for Evaluating Pembrolizumab Plus Paclitaxel With/Without Bevacizumab in PROC

November 4th 2025

Nicoletta Colombo, MD, PhD, discusses the rationale for evaluating pembrolizumab plus weekly paclitaxel with/without bevacizumab in recurrent PROC.

Positive KEYNOTE-B96 Data Show Role for Immunotherapy–Based Regimens in PROC

November 4th 2025

Nicoletta Colombo, MD, PhD, discusses clinical implications for integrating immunotherapy into the treatment arsenal for platinum-resistant ovarian cancer.

OncLive’s October EMA Regulatory Recap: Key EU Approvals in Oncology

November 3rd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in October 2025.

Five Under 5: Top Oncology Videos for the Week of 10/26

November 2nd 2025

The top 5 OncLive TV videos of the week cover insights in myeloproliferative neoplasms, lung cancer, ovarian cancer, and prostate cancer.

Mirvetuximab Soravtansine Receives Positive Reimbursement Recommendation From Canada’s Drug Agency for Platinum-Resistant Ovarian Cancer

October 31st 2025

Mirvetuximab soravtansine has received a positive reimbursement recommendation in Canada under the Target Zero initiative for platinum-resistant ovarian cancer.

Dr Elias on Outcomes With Niraparib Maintenance Therapy in Ovarian Cancer

October 31st 2025

Kevin Elias, MD, discusses efficacy data from the PRIMA and NOVA trials evaluating niraparib as maintenance therapy in ovarian cancer.

Dr Lynam on the Clinical Implications of Targeted Therapies in Ovarian Cancer

October 29th 2025

Sarah Lynam, MD, discusses the clinical applicability of mirvetuximab soravtansine and trastuzumab deruxtecan in recurrent ovarian cancer.

Emerging Agents and Paradigm Shifts in Gynecologic Cancer: Expert Takeaways From ESMO 2025

October 28th 2025

Experts reflect on pivotal data, emerging agents, and notable advancements in gynecologic cancer spotlighted during the 2025 ESMO Congress.

Dr Salutari on the Rationale for Evaluating Relacorilant Plus Nab-Paclitaxel in PARP Inhibitor–Treated PROC

October 23rd 2025

Vanda Salutari, MD, discusses the rationale for examining relacorilant plus nab-paclitaxel in PARP inhibitor–treated platinum-resistant ovarian cancer.

Dr Lynam on the Efficacy of Trastuzumab Detruxtecan in HER2-Expressing Ovarian Cancer

October 22nd 2025

Sarah Lynam, MD, details key efficacy data from the phase 2 DESTINY-PanTumor02 trial, evaluating trastuzumab deruxtecan in HER2-expressing solid tumors.